Trulicity ® (dulaglutid) injektion

För fullständig produktresumé för Trulicity® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Trulicity® (dulaglutid): HbA1c minskning beroende på ursprungsvärde

Behandling med dulaglutid var förknippad med en större minskning av HbA1c-nivåerna hos patienter med högre ursprungsvärde av HbA1c.

Post Hoc Analysis - Baseline HbA1c Level <8.5% or ≥8.5%

A post hoc analysis of 7 AWARD studies, AWARD-1 to -6 and -8, assessed the efficacy and safety of once-weekly dulaglutide 1.5 mg and dulaglutide 0.75 mg in adults with T2DM when stratified into subgroups by baseline HbA1c levels of <8.5% and ≥8.5%.1

At 6 and 12 months, both subgroups of patients treated with once-weekly dulaglutide 1.5 mg or dulaglutide 0.75 mg demonstrated a significant LSM reduction in HbA1c levels from baseline, with a greater LSM reduction in HbA1c levels noted in patients with a baseline HbA1c level ≥8.5% compared with those with a baseline HbA1c level <8.5% (Table 1).1

Table 1. Change in HbA1c Levels at 6 and 12 Months With Dulaglutide 1.5 mg or Dulaglutide 0.75 mg Stratified by Baseline HbA1c Levels - Pooled Analysis From AWARD-1 to -6 and -8 Studies1

HbA1c, %a 
 

DU 1.5 mg 

DU 1.5 mg

DU 0.75 mg

DU 0.75 mg


Baseline HbA1c <8.5%
(n=1289)

Baseline HbA1c ≥8.5%
(n=666)

Baseline HbA1c <8.5%
(n=963)

Baseline HbA1c ≥8.5%
(n=452)

Baseline, mean (SD)

7.5 (0.5)

9.3 (0.8)

7.5 (0.6)

9.4 (0.8)

Change from baseline to 6 months

-1.02
(-1.12, -0.93)

-1.86
(-1.97, -1.75)

-0.83
(-0.93, -0.73)

-1.75
(-1.87, -1.62)

Change from baseline to 12 months

-0.98
(-1.09, -0.88)

-1.80
(-1.92, -1.68)

-0.75
(-0.86, -0.63)

-1.61
(-1.75, -1.48)

Abbreviations: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; DU = dulaglutide; HbA1c = glycated hemoglobin; LSM = least squares mean.

a Data presented as LSM (95% CI) unless otherwise indicated. AWARD-1 to -5 studies reported data at both 6 and 12 months; AWARD-6 and -8 studies reported data at 6 months only.

Post Hoc Analysis - Baseline HbA1c Level ≤9% or >9%

A post hoc analysis of AWARD-4 and -9 assessed the efficacy and safety of once-weekly dulaglutide 1.5 mg combined with prandial or basal insulin in poorly-controlled patients with T2DM on prior insulin therapy when stratified into subgroups by baseline HbA1c levels of ≤9% and >9%.2

At 6 months, both subgroups of patients treated with once-weekly dulaglutide 1.5 mg demonstrated a significant LSM reduction in HbA1c levels from baseline (p<.001), with a greater LSM reduction in HbA1c levels noted in patients with a baseline HbA1c level >9% compared with those with a baseline HbA1c level ≤9% (Table 2).2

Table 2. Change in HbA1c Levels at 6 Months With Dulaglutide 1.5 mg Stratified by Baseline HbA1c Levels - Pooled Analysis From AWARD-4 and -9 Studies2

HbA1c, %

Baseline HbA1c ≤9%
(n=325)

Baseline HbA1c >9%
(n=118)

Baseline, mean (SD)

8.0 (0.6)

9.7 (0.6)

Change from baseline to 6 months, LSM 

-1.3a

-2.5a 

Abbreviations: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; HbA1c = glycated hemoglobin; LSM = least squares mean.

a p<.001 vs baseline.

References

1. Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018;20(2):409-418. http://dx.doi.org/10.1111/dom.13086

2. Pantalone KM, Patel H, Yu M, Fernández Landó L. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Diabetes Obes Metab. 2018;20(6):1461-1469. http://dx.doi.org/10.1111/dom.13252

Glossary

AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes

HbA1c = glycated haemoglobin

LSM = least squares mean

T2DM = type 2 diabetes mellitus

Datum fӧr senaste ӧversyn 2018 M10 25


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss